PF-562271

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H20F3N7O3S
Molecular Weight	507.489
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C1=NC=CC=C1CNC2=C(C=NC(NC3=CC=C4NC(=O)CC4=C3)=N2)C(F)(F)F)S(C)(=O)=O

InChI

InChIKey=MZDKLVOWGIOKTN-UHFFFAOYSA-N

InChI=1S/C21H20F3N7O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30)

HIDE SMILES / InChI

Molecular Formula	C21H20F3N7O3S
Molecular Weight	507.489
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Focal adhesion kinase 1 15 Target ID: Q05397 Gene ID: 5747.0 Gene Symbol: PTK2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18339875	Inhibitor 8297		1.5 nM [IC50]

PubMed

Title	Date	PubMed
Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.	2009 May	19458500
Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.	2010 Dec 9	20802523
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.	2010 Jul 1	20495381

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:52:58 GMT 2023` Edited by `admin` on `Fri Dec 15 15:52:58 GMT 2023`
Record UNII	K5BX8ZA7UF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PF-562271

Code

English

PF-562,271

Code

English

PF-00562271 FREE BASE

Common Name

English

PF-562271 [WHO-SDG]

Common Name

English

PF-562271 FREE BASE

Common Name

English

Code System Code Type Description

FDA UNII

K5BX8ZA7UF